GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MannKind Corporation
MannKind, a biopharmaceutical company, focuses on inhaled medications, primarily insulin. Its price is highly volatile and depends on sales of its flagship product, Afrezza, as well as the success of partnerships to apply its technology to other drugs.
Share prices of companies in the market segment - Pharma other
MannKind, a biopharmaceutical company, focuses on inhaled medications, primarily insulin. We classify it in the Pharma Other sector, and the chart below shows the dynamics of the entire segment, where the company's value depends on sales of its core product and partnerships.
Broad Market Index - GURU.Markets
MannKind Corporation is a biopharmaceutical company specializing in the development of inhaled therapeutic products, including inhaled insulin. It is a component of the GURU.Markets index. The chart below shows the market. See how MannKind shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
MNKD - Daily change in the company's share price MannKind Corporation
Shares of MannKind, a biopharmaceutical company, exhibit high volatility, as measured by change_co. This metric reflects sensitivity to sales of its inhaled insulin and development news. This metric is a key component of System.GURU.Markets' biotech sector analysis formulas.
Daily change in the price of a set of shares in a market segment - Pharma other
MannKind Corporation is a pharmaceutical company with a unique technology. This chart illustrates the extreme volatility of the biotech sector. A comparison with MNKD, whose success depends on its inhaled insulin, helps assess its specific risks.
Daily change in the price of a broad market stock, index - GURU.Markets
MannKind is a biopharmaceutical company known for its inhaled insulin technology. The pharmaceutical sector is known for its high volatility. The chart below shows average daily fluctuations in this industry, allowing one to assess how MannKind's performance aligns with overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MannKind Corporation
MannKind is a biopharmaceutical company specializing in inhaled medications. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform and delivery technology.
Annual dynamics of market capitalization of the market segment - Pharma other
MannKind Corporation is a biopharmaceutical company specializing in the development of inhaled drugs. Its unique drug delivery technology is its primary asset. This chart shows how the market views the commercial success of its approved inhaled insulin and the potential of its R&D.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MannKind is a biopharmaceutical company whose stock performance is driven by sales success of its inhaled insulin and progress in research. The company's business is not dependent on economic cycles. The chart reflects its success in commercializing its unique technology, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MannKind Corporation
MannKind, a biopharmaceutical company known for its inhaled insulin Afrezza, is a company whose monthly fluctuations reflect the sales dynamics of this niche product, as well as news about the development of other drugs based on its unique inhalation platform.
Monthly dynamics of market capitalization of the market segment - Pharma other
MannKind Corporation specializes in developing inhaled medications, their flagship product being inhaled insulin. This is an innovative method of delivering medications for the treatment of chronic diseases. The graph below shows the overall dynamics in the pharmaceutical sector, where new drug delivery methods have the potential to change the standard of care.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MannKind Corporation focuses on inhaled medications, primarily for diabetes. Its stock price depends on the successful commercialization of its unique drug delivery technology. This is a question of whether the innovative product can conquer the market, and it has less to do with general sentiment than with company news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MannKind Corporation
Shares of MannKind Corporation, a company focused on developing inhaled medications, reflect the challenges and opportunities in drug delivery on a weekly basis. Price movements reflect sales of their inhaled insulin and advances in applying their technology to other conditions.
Weekly dynamics of market capitalization of the market segment - Pharma other
Innovative drug delivery methods are a niche in the pharmaceutical industry, where weekly growth depends on clinical data and partnerships. The search for alternatives to injections is a common trend for many companies. The chart illustrates this backdrop, against which MannKind is advancing its inhalation technology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MannKind Corporation has developed inhaled insulin. The company operates in the highly competitive diabetes market. The chart below shows how MannKind shares compare to the market: do they live their own lives, reacting to sales volumes and news, or do the overall dynamics of the biotech sector and the market determine their trend?
Market capitalization of the company, segment and market as a whole
MNKD - Market capitalization of the company MannKind Corporation
MannKind's market capitalization tells the story of a long and arduous struggle to commercialize a unique inhaled insulin technology. The chart reflects decades of hope and disappointment. Its recent performance reflects the market's attempt to evaluate new projects and the platform's potential for delivering other drugs through the lungs.
MNKD - Share of the company's market capitalization MannKind Corporation within the market segment - Pharma other
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, the best-known of which is inhaled insulin. Its market share is still small, but reflects the potential of its unique drug delivery technology. The chart tells the story of the struggle for recognition of its innovative approach.
Market capitalization of the market segment - Pharma other
MannKind Corporation is a biopharmaceutical company known for its inhaled insulin technology. The chart below shows the overall market capitalization of this sector. Its volatility reflects the challenges the company faces in commercializing its innovative, yet niche, drug delivery technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
MannKind Corporation has developed a technology for inhaled drug delivery, most famously used in inhaled insulin. Its market capitalization is a bet on this platform. The chart below shows the economic weight of companies with unique drug delivery technologies.
Book value capitalization of the company, segment and market as a whole
MNKD - Book value capitalization of the company MannKind Corporation
The foundation of MannKind Corporation is its manufacturing facilities for inhaled insulin and a portfolio of patents for pulmonary drug delivery technology. This is real, science-intensive capital, offering an alternative to injections. How has this innovative, yet niche, asset evolved? The chart below tells its complex story.
MNKD - Share of the company's book capitalization MannKind Corporation within the market segment - Pharma other
MannKind Corporation developed and manufactures inhaled insulin at its unique facility in Connecticut. The chart shows the share of this specialized manufacturing facility in the pharmaceutical sector, reflecting the physical foundation of its innovative drug delivery technology.
Market segment balance sheet capitalization - Pharma other
Biopharmaceuticals, as the BCap_Seg chart shows, require investment in science rather than early-stage manufacturing. MannKind is uniquely positioned: it owns inhalation drug delivery technology and manufacturing capacity, making it more capital-intensive than pure research companies.
Book value of all companies included in the broad market index - GURU.Markets
MannKind Corporation's assets include a unique plant in Connecticut designed for the production of inhaled insulin. Its book value reflects the physical capital invested in cutting-edge manufacturing technology and capabilities that distinguish the company from others in the pharmaceutical industry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MannKind Corporation
MannKind Corporation has developed inhaled insulin. The company's book value doesn't reflect the potential of this unique technology. Market capitalization is a bet on whether the company will successfully commercialize its product and transform the diabetes treatment market. The MvsBCap chart will be highly sensitive to sales and partnership news.
Market to book capitalization ratio in a market segment - Pharma other
MannKind Corporation is focused on developing inhaled therapeutic products. The company's core asset is its technological platform and its potential for application in various drug applications. This metric reflects investor expectations regarding the future success of this technology.
Market to book capitalization ratio for the market as a whole
MannKind Corporation is focused on developing inhaled therapeutics. Its core asset is the Afrezza technology. The company's market value depends on the successful commercialization of this platform for various drugs. This metric demonstrates a typical biotech situation where future expectations are worth more than current assets.
Debts of the company, segment and market as a whole
MNKD - Company debts MannKind Corporation
MannKind Corporation, a biopharmaceutical company focused on inhaled drugs, uses debt financing to support the production and commercialization of its core product, as well as R&D. Bringing its unique drug delivery technology to market requires significant marketing and production costs. This chart reflects its financing strategy.
Market segment debts - Pharma other
MannKind Corporation is focused on the development and commercialization of inhaled therapeutics, primarily for diabetes. For a pharmaceutical company advancing a unique technology, managing finances to support manufacturing and marketing is a key challenge. This chart illustrates how the company finances its operating activities.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MannKind Corporation
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products. The chart shows how the company finances its innovations. For a biopharma with a unique drug delivery technology but a narrow portfolio, debt is a risk factor. It reflects the company's dependence on the success of one or more key products.
Market segment debt to market segment book capitalization - Pharma other
MannKind Corporation is focused on developing inhaled therapeutics. For the pharmaceutical industry, this chart reflects general trends in R&D funding and the commercialization of new drugs. It provides context for evaluating the company's financial strategy, especially after the launch of its key product.
Debt to book value of all companies in the market
MannKind Corporation is a pharmaceutical company. Its funding depends on the success of sales and development. This chart reflects the overall risk appetite in the economy. For a company in this industry, it helps understand how its funding model aligns with the overall market situation and investor confidence in its products.
P/E of the company, segment and market as a whole
P/E - MannKind Corporation
The chart for MannKind Corporation, the company that developed inhaled insulin, shows how investors evaluate the prospects of its unique product. Fluctuations in this indicator reflect expectations for sales growth, potential partnerships, and the company's ability to make its technology a standard of care for a specific patient group.
P/E of the market segment - Pharma other
This chart shows the average P/E for the pharmaceutical industry, where MannKind offers a unique product. Comparing the company's P/E to this average helps understand how the market values its inhaled insulin technology compared to other, more traditional pharmaceutical products and business models.
P/E of the market as a whole
MannKind Corporation specializes in the development and commercialization of inhaled therapeutic products, including inhaled insulin. This is an innovative approach to drug delivery. Given the overall biotech sentiment, which can be compared with this chart, MannKind's valuation reflects investors' confidence in the potential of its unique technology and future products.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MannKind Corporation
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, including inhaled insulin. The chart shows speculative future revenue expectations, which depend on sales growth of its core product and success in developing new drugs based on its technology platform.
%20P%2FE%20MannKind%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MannKind-Corporation&v=1772694598043 "Chart of the company's future (projected) P/E MannKind Corporation")
Future (projected) P/E of the market segment - Pharma other
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, most notably inhaled insulin. This chart shows future profitability expectations in the pharmaceutical sector. It helps understand the market's confidence in the potential of inhaled drug delivery technology and sales growth.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772694598058 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
MannKind Corporation focuses on the development and commercialization of inhaled therapeutics, most notably inhaled insulin. It is a biopharmaceutical company with a unique technology. This overall risk appetite chart shows how willing investors are to invest in companies with innovative but niche products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772694598100 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MannKind Corporation
MannKind Corporation is a biopharmaceutical company specializing in the development of inhaled therapeutics, most notably inhaled insulin. Profit is driven by sales of this unique product. This chart shows financial results reflecting the challenges and successes of commercializing this innovative drug delivery system.
Profit of companies in the market segment - Pharma other
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, most prominently inhaled insulin. This innovative drug delivery method is a key focus for the pharmaceutical industry, where new drug delivery methods can open new markets and change treatment standards.
Overall market profit
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products, including inhaled insulin. The company's prospects depend on the successful marketing of its products and the approval of new ones. This business is located in the healthcare sector, and its dynamics are not closely related to the general economic cycles depicted in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MannKind Corporation
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products, the most well-known of which is inhaled insulin. Future profits depend on sales growth for this product and the success of other developments. This chart shows analyst expectations regarding the adoption of inhaled technologies in medical practice.
%20profit%20of%20the%20company%20MannKind%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MannKind-Corporation&v=1772694598153 "Graph of future (projected) profit of the company MannKind Corporation")
Future (predicted) profit of companies in the market segment - Pharma other
MannKind Corporation is focused on the development and commercialization of inhaled therapeutics. Its key product is inhaled insulin for diabetics. The company's success depends on the expansion of this technology. This chart shows expected profitability for the pharmaceutical sector, providing context for evaluating MannKind's innovative approach to drug delivery.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772694598176 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
MannKind Corporation is a biopharmaceutical company specializing in the development and commercialization of inhaled therapeutic products. Its success depends on sales of existing drugs and the approval of new ones. This economic outlook impacts the overall solvency of the healthcare system and patient access to medications.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772694598180 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MannKind Corporation
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, including inhaled insulin. The company's revenue depends on the successful sales of its key product. This chart shows how investors assess the market potential of this unique drug delivery technology.
P/S market segment - Pharma other
MannKind Corporation specializes in the development and commercialization of inhaled therapeutic products. Their flagship product is inhaled insulin, offering an alternative to traditional injections for people with diabetes. This chart reflects the average revenue estimate for the pharmaceutical sector, providing insight into the market's perception of the potential of inhaled delivery technology.
P/S of the market as a whole
MannKind Corporation specializes in developing inhaled therapeutics, the most well-known of which is inhaled insulin. The company offers a unique drug delivery method. This chart helps us understand that the valuation of such biopharmaceutical companies often depends not on current revenue, but on the potential of their technology platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MannKind Corporation
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products, the most prominent of which is inhaled insulin. The company's revenue valuation is critically important. It reflects investors' confidence in the growth of its core product and the potential of other inhaled drugs in development in the pharmaceutical market.
%20P%2FS%20MannKind%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MannKind-Corporation&v=1772694598233 "The graph of the company's future (projected) P/S MannKind Corporation")
Future (projected) P/S of the market segment - Pharma other
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, most prominently inhaled insulin. This chart reflects how investors view the company's future revenues relative to the pharmaceutical sector. It demonstrates the market's confidence in the potential of its inhaled drug delivery technology and the growth of its existing products.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772694598255 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
MannKind Corporation specializes in the development of inhaled therapeutics. The company represents the innovative pharmaceutical sector. Its potential is not always tied to current economic cycles, but its technologies can create new markets that influence future forecasts, as reflected in the chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772694598266 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MannKind Corporation
This metric for MannKind Corporation reflects revenue from sales of Afrezza inhaled insulin and revenue from collaborations with other pharmaceutical companies. The graph's dynamics demonstrate how successfully the company is promoting its unique product in the diabetes treatment market and monetizing its technology platform through partnerships.
Sales of companies in the market segment - Pharma other
MannKind Corporation is focused on developing inhaled therapeutic products. Its primary revenue is generated from sales of Afrezza inhaled insulin. Its revenue structure may also include revenue from collaborations with other pharmaceutical companies, demonstrating the potential of its technology platform beyond diabetes.
Overall market sales
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, primarily for the treatment of diabetes. The company's success depends on the acceptance of its technologies by the medical community and patients. This overall economics chart serves only as a backdrop for the company, whose growth is driven by healthcare innovation and treatment effectiveness.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MannKind Corporation
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products. Its primary product is inhaled insulin. Future revenue depends on sales growth of this drug and the success of other developments. The chart reflects analysts' forecasts for demand for the company's unique drug delivery technology.
%20sales%20of%20the%20company%20MannKind%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MannKind-Corporation&v=1772694598317 "Schedule of future (projected) sales of the company MannKind Corporation")
Future (projected) sales of companies in the market segment - Pharma other
MannKind Corporation specializes in the development and commercialization of inhaled therapeutics, particularly insulin. This chart shows sales forecasts for the pharmaceutical market. Is demand for innovative drug delivery methods expected to grow? This allows us to assess the overall trend MannKind is focusing on.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772694598344 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products, primarily for the treatment of diabetes. Its success depends on the acceptance of its products by physicians and patients, as well as on clinical development. General economic trends, reflected in this chart, have minimal impact on its business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772694598348 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MannKind Corporation
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, the most well-known of which is inhaled insulin. This chart shows the financial trajectory of the company, which is advancing an innovative drug delivery method. Its profitability depends on sales growth and physician and patient acceptance of this alternative to traditional injections.
Market segment marginality - Pharma other
MannKind Corporation is a biopharmaceutical company specializing in the development of inhaled therapeutics. Its primary product is inhaled insulin. This metric reflects the company's financial position, whose profitability depends on the successful development of its unique drug delivery technology and its expansion to other therapeutics.
Market marginality as a whole
MannKind Corporation focuses on developing inhaled therapeutic products, particularly for diabetes. The company's success depends on the acceptance of its technology by the medical community and patients. This gross profitability chart reflects the state of the economy, which impacts healthcare costs and the system's ability to implement new, albeit potentially expensive, medications.
Employees in the company, segment and market as a whole
Number of employees in the company MannKind Corporation
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, primarily inhaled insulin. Its team includes specialists in manufacturing, research, and sales. This chart shows how the company manages its staff to scale up production and promote its unique product to physicians.
Share of the company's employees MannKind Corporation within the market segment - Pharma other
MannKind Corporation focuses on the development and commercialization of inhaled therapeutics. Its flagship product is inhaled insulin. Manufacturing and research require a team of scientists, engineers, and quality specialists. This graph shows the company's market share in the pharmaceutical industry, which is an indicator of its manufacturing and R&D capacity.
Number of employees in the market segment - Pharma other
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products, including inhaled insulin. This chart shows its presence in the pharmaceutical industry. MannKind's innovative approach to drug delivery sets it apart from traditional manufacturers, and its sector dynamics reflect overall healthcare trends.
Number of employees in the market as a whole
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products, primarily for diabetes. The growth of its team of scientists and sales specialists reflects its success in advancing its unique technology. Hiring dynamics here, against the overall picture in this chart, depend on regulatory approval and market acceptance.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MannKind Corporation (MNKD)
MannKind Corporation specializes in inhaled therapeutics. This chart shows how the market values their unique technology platform. The company's value is derived from the patents on their drug delivery technology. The high market capitalization per employee reflects the value of this intellectual property.
%20of%20the%20company%20MannKind%20Corporation%20(MNKD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MannKind-Corporation-MNKD&v=1772694598462 "Chart of market capitalization per employee (in thousands of dollars) of the company MannKind Corporation (MNKD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
MannKind (MNKD) is a biopharmaceutical company specializing in inhaled medications. Their primary product is inhaled insulin (Afrezza). This chart shows the industry average cost per employee. It helps assess how the market values their inhaled delivery technology (Technosphere) and the commercial success of Afrezza per employee.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772694598484 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
MannKind Corporation is a biopharmaceutical company focused on developing inhaled medications, such as inhaled insulin. Its value is driven by its unique technology platform. The chart shows a high valuation per employee, as the market believes in the potential of pulmonary drug delivery technology for the treatment of various diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772694598496 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MannKind Corporation (MNKD)
MannKind is a biopharmaceutical company known for its inhaled drug technology (e.g., Afrezza inhaled insulin). This chart shows how successfully the company is commercializing its unique platform. It reflects the balance between R&D and manufacturing costs and the ability to generate revenue from drug sales.
%20Chart%20MannKind%20Corporation%20(MNKD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MannKind-Corporation-MNKD&v=1772694598510 "Company Profit Per Employee (in thousands of dollars) Chart MannKind Corporation (MNKD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
MannKind (MNKD) is an R&D biotech company (Afrezza, an inhaled insulin company). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (biotech) is high (if there's a hit). The benchmark reflects a "one-hit business": the sector spends millions on R&D, and a single successful drug recoups all costs.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772694598524 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
MannKind Corporation is a biopharmaceutical company known for its inhaled insulin (Afrezza). It is an R&D company that also engages in contract manufacturing. This chart shows how Afrezza sales and manufacturing revenue cover R&D and marketing expenses. It's a difficult balance for a company trying to bring its product to the mass market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772694598626 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MannKind Corporation (MNKD)
MannKind Corporation focuses on developing inhaled therapeutics. For a biopharmaceutical company, this figure is a measure of commercial success. Significant growth in revenue per employee will indicate successful product launch and acceptance by physicians and patients, monetizing years of research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MannKind-Corporation-MNKD&v=1772694598652 "Sales chart per company employee MannKind Corporation (MNKD)")
Sales per employee in the market segment - Pharma other
MannKind Corporation is a biotech company known for its inhaled insulin (Afrezza). This is a complex product, requiring both manufacturing and specialized marketing. This graph shows the average production in the sector. For MNKD, this is an indicator of how productive their sales and R&D teams are in promoting this niche drug and developing new ones.
Sales per employee for the market as a whole
MannKind Corporation is focused on the development and commercialization of inhaled therapeutics, with its flagship product being inhaled insulin. This indicator demonstrates how effectively the company can manufacture and market its niche product. It represents a balance between R&D, specialized manufacturing, and sales efforts.
Short shares by company, segment and market as a whole
Shares shorted by company MannKind Corporation (MNKD)
MannKind (MNKD) is a biopharmaceutical company known for its inhaled insulin Afrezza. The company is also developing other drugs. This chart tracks bearish bets. The high short interest reflects years of market skepticism about the commercial success of Afrezza, which never became a blockbuster, and doubts about the success of the company's other developments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MannKind-Corporation-MNKD&v=1772694598677 "Short Shares Chart for the Company MannKind Corporation (MNKD)")
Shares shorted by market segment - Pharma other
MannKind Corporation (MNKD) is a biopharmaceutical company known for its inhaled insulin Afrezza. This chart aggregates short positions across the pharmaceutical sector. It reflects investor skepticism regarding the commercial success of niche drugs and the intense competition in the diabetes treatment market, which impacts the entire segment.
Shares shorted by the overall market
MannKind (MNKD) is a biotech focused on inhaled drugs. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with approved drugs, often suffer sell-offs when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MannKind Corporation (MNKD)
MannKind Corporation (MNKD) is a biopharmaceutical company known for its inhaled insulin drug Afrezza. Their business is attempting to change the paradigm of diabetes treatment. This chart is an oscillator reflecting sentiment. It shows "overheated" (above 70) on positive sales news or "oversold" (below 30) amid concerns about competition or financial results.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MannKind-Corporation-MNKD&v=1772694598704 "RSI 14 indicator chart for the company's stock MannKind Corporation (MNKD)")
RSI 14 Market Segment - Pharma other
MannKind (MNKD) specializes in inhaled drugs, with Afrezza (inhaled insulin) as its flagship. The RSI_14_Seg for "Pharma Other" (biotech) shows the overall sentiment. The chart helps us understand: is MNKD's volatility a reaction to its trials, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
MannKind (MNKD) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MNKD (MannKind Corporation)
MannKind Corporation is a biopharmaceutical company known for its inhaled insulin technology (Afrezza) and the development of inhaled versions of other drugs. This chart shows the average analyst forecast. Their target prices depend on sales growth for Afrezza and the success of clinical trials of drug candidates using their inhaled platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MNKD-MannKind-Corporation&v=1772694598739 "A chart showing analyst consensus forecasts for the expected stock price. MNKD (MannKind Corporation)")
The difference between the consensus estimate and the actual stock price MNKD (MannKind Corporation)
MannKind Corporation is a biopharmaceutical company whose fate is tied to a single product: Afrezza, the world's only inhalable insulin. Despite its technology, they have been struggling for years to gain market acceptance. This chart shows how analysts assess their chances of achieving a commercial breakthrough for this unique drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MNKD-MannKind-Corporation&v=1772694598759 "A chart showing the difference between the consensus forecast and the actual stock price. MNKD (MannKind Corporation)")
Analyst consensus forecast for stock prices by market segment - Pharma other
MannKind is a biopharmaceutical company known for its inhaled insulin Afrezza and its pulmonary drug delivery technology Technosphere. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe in the increased adoption of inhaled insulin over injections.
Analysts' consensus forecast for the overall market share price
MannKind Corporation is a biopharmaceutical company known for its inhaled insulin technology (Afrezza). They are also developing inhaled versions of other medications. This chart shows overall market sentiment. For MannKind, which is struggling to gain acceptance for its technology, it's important to understand how these expectations (risk appetite) influence funding for its development. (348)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MannKind Corporation
MannKind (MNKD) is the biopharmaceutical company behind Afrezza, a unique inhaled insulin. Their business is battling to introduce this unconventional delivery method against the dominant injections. This chart is an indicator of their niche. It measures the slow but growing demand for Afrezza and their ability to leverage their manufacturing platform for other drugs.
AKIMA Market Segment Index - Pharma other
MannKind (MNKD) is a biotech pioneer in inhalation technologies; the company produces a unique inhaled insulin (Afrezza) and is exploring using this platform for other drugs. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does MNKD's technological (inhaler) platform differentiate it from the average pharmaceutical company?
The AKIM Index for the overall market
MannKind is a biopharmaceutical company known for its inhaled insulin (Afrezza) and pulmonary drug delivery technology. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this niche company in the treatment of diabetes and other diseases compares to overall economic trends.
